Search Videos and More

Showing 1 - 12 of 111 results

Previous| 1 | 2 | 3 ...10 |Next


ESMO26: Antonio Giordano, MD, PhD, on FOURLIGHT Video

ESMO26: Antonio Giordano, MD, PhD, on FOURLIGHT

Antonio Gioradano, MD, presents efficacy and safety of atirmociclib + fulvestrant in HR+/HER2- advanced breast cancer after progressing on prior CDK4/6 inhibitor - data from phase 2 FOURLIGHT-1 study.
ESMO26: Paolo Tarantino, MD on ADC Resistance in Breast Cancer Video

ESMO26: Paolo Tarantino, MD on ADC Resistance in Breast Cancer

Paolo Tarantino, MD, of Dana-Farber Cancer Institute, shows that antibody-drug conjugate (ADC) resistance appears to be driven by complex molecular adaptations beyond target modulation.
Turning Promise Into Progress News

Turning Promise Into Progress

How new cancer treatments reach patients and help shape the next cycle of discovery
Treatment Guideline: First-Line Treatment of HER2-Positive Metastatic Breast Cancer Document

Treatment Guideline: First-Line Treatment of HER2-Positive Metastatic Breast Cancer

The Breast Oncology Center held meetings to discuss recommendations regarding first-line treatment of patients with HER2-positive metastatic breast cancer.
ESMO Congress 2026 Symposium

ESMO Congress 2026

Preview news releases and presentations by Dana-Farber Physician-Scientists at this year's ESMO Congress 2026 in Madrid, Spain, October 23 - 27, 2026.
Treatment Guideline: Elinzanetant in Patients with a Breast Cancer and Vasomotor Symptoms Document

Treatment Guideline: Elinzanetant in Patients with a Breast Cancer and Vasomotor Symptoms

The Breast Oncology Center held meetings to discuss recommendations regarding the use of elinzanetant in patients with a history of breast cancer and vasomotor symptoms.
Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer News

Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer

Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared to a standard combination approach.
Building a System of Focused Care for Lobular Breast Cancer News

Building a System of Focused Care for Lobular Breast Cancer

How Dana-Farber investigators are pioneering new approaches to help understand, diagnose, and treat this distinct form of breast cancer
2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer Video

2026 ASCO Breast Cancer Highlights: Triple Negative Breast Cancer

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.
2026 ASCO Breast Cancer Highlights: BWEL Video

2026 ASCO Breast Cancer Highlights: BWEL

Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD discuss new research from the Breast Cancer Weight Loss (BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists.
2026 ASCO Breast Cancer Highlights: HER2CLIMB-05 Video

2026 ASCO Breast Cancer Highlights: HER2CLIMB-05

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the HER2Climb-05 trial and how it impacts treatment for HER2+ metastatic breast cancer
2026 ASCO Breast Cancer Highlights: Neo-Healer Video

2026 ASCO Breast Cancer Highlights: Neo-Healer

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the new Neo-Healer trial in HER2+ breast cancer.

Showing 1 - 12 of 111 results

Previous| 1 | 2 | 3 ...10 |Next